A Novel Technique to Remove Iatrogenic Pulmonary Parenchymal Chest Tube (PPcT): A Retrospective Analysis From a Tertiary Care Thoracic Surgery Centre
NCT ID: NCT07148661
Last Updated: 2025-08-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
163 participants
OBSERVATIONAL
2024-05-01
2025-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Diagnosing PPcT is often challenging because the clinical presentation and radiographic findings are nonspecific, and the condition may be overlooked, particularly in patients with pre-existing pulmonary disease. Computed tomography (CT) of the chest remains the gold standard for accurate diagnosis.
At our institution, we have developed and successfully implemented a stepwise, minimally invasive technique for the safe removal of PPcT over the last 19 years (since 2006), thereby avoiding thoracotomy or other invasive procedures. Once PPcT is confirmed by CT scan-while carefully differentiating true parenchymal tube placement from tubes merely located within fissures-we adopt a three-stage removal strategy:
Initial healing phase: The tube is left in situ for approximately two weeks to allow for local fibrosis and healing around the injured parenchyma, which reduces the risk of bleeding and air leak during subsequent manipulation.
Gradual staged retraction: After this period, the tube is retracted by approximately 2 cm and secured again. In cases where the tube is tightly adherent, it is rotated 360° along its axis to release any fibrous adhesions. The patient is then observed for 24 hours, with close monitoring for hemodynamic instability, hemorrhage, or air leak, and a chest radiograph is obtained to confirm tube position.
Subsequent retractions: If the patient remains stable, they are discharged and readmitted at 7-day intervals for further staged retractions of approximately 2 cm each. This process continues until the fenestrations ("eyes") of the tube exit the pleural cavity, at which point the tube is safely removed. In many cases, the tube can be removed after the first or second stage if the fenestrations have already cleared the pleural space, thereby preventing pneumothorax.
This technique has consistently yielded excellent results in our experience, allowing safe removal of PPcT while minimizing morbidity and eliminating the need for thoracotomy or video-assisted thoracoscopic surgery (VATS) for tube retrieval.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PPcT Group
Participants that have been diagnosed with Iatrogenic injury to lung in case of Pulmonary Parenchymal chest tube (PPcT)
Removal of PPcT
Iatrogenic Pulmonary Parenchymal Chest Tube is removed as a staged procedure in which gradual retraction of 2cm of chest tube is done from lung parenchyma keeping an eye on the hemodynamic status of Patient.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Removal of PPcT
Iatrogenic Pulmonary Parenchymal Chest Tube is removed as a staged procedure in which gradual retraction of 2cm of chest tube is done from lung parenchyma keeping an eye on the hemodynamic status of Patient.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Health Sciences Lahore
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Zeeshan Sarwar
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Muhammad Shoaib Nabi, Clinical Professor
Role: PRINCIPAL_INVESTIGATOR
Services Institute of Medical Sciences (SIMS), Services Hospital, Lahore
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Services Institute of Medical Sciences(SIMS), Services Hospital.
Lahore, Punjab Province, Pakistan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRB/2025/1654/SIMS
Identifier Type: -
Identifier Source: org_study_id